Five Late-Breaking Studies To Look Out For At ASCO
Executive Summary
Ahead of the American Society of Clinical Oncology meeting in early June, analysts at Biomedtracker have highlighted select high-impact late-breaking abstracts that are due to presented, including therapies from AbbVie, Gilead Sciences, Pfizer, Takeda, Amgen, AstraZeneca and Daiichi Sankyo.
You may also be interested in...
AbbVie/J&J Withdrawal Of Imbruvica Indications Clears Space For Competitors
The BTK inhibitor’s exit from MCL and MZL after lackluster Phase III confirmatory trial results gives AstraZeneca’s Calquence and BeiGene’s Brukinsa a potential shot at claiming the space.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: a US setback for UCB; Lilly challenges Novo’s GLP franchise; Seagen searches for CEO after scandal; Hengrui hopes for US PD-1 success; and a look ahead at ASCO.
AstraZeneca/Daiichi's Enhertu Expansion Strategy Progresses With New Approval
Enhertu secured US FDA approval as a second-line treatment in HER2-positive breast cancer, where it is poised to become the new standard of care.